THRX insider filings

Theseus Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-02-14. Screen THRX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for THRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Theseus Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2024-02-144Dahms Bradford D. — President and CFOCode (U): 8,150.23 · Disposition to issuer (D): 17,500 (derivative) · Disposition to issuer (D): 332,114 (derivative)EDGAR
2024-02-144Yi Kathy — DirectorDisposition to issuer (D): 3,250 (derivative) · Disposition to issuer (D): 99,634 (derivative)EDGAR
2024-02-144Dukes Iain D. — DirectorCode (U): 388,324 · Disposition to issuer (D): 3,250 (derivative) · Disposition to issuer (D): 344,344 (derivative) · Disposition to issuer (D): 36,066 (derivative) · Disposition to issuer (D): 61,549 (derivative)EDGAR
2024-02-144Stein Steven H — DirectorDisposition to issuer (D): 3,250 (derivative)EDGAR
2024-02-144GORDON CARL L — Director, 10% ownerCode (U): 17,063,000 · Code (U): 650,600 · Disposition to issuer (D): 3,250 (derivative)EDGAR
2024-02-144HAYDEN DONALD J JR — DirectorCode (U): 10,000 · Disposition to issuer (D): 3,250 (derivative)EDGAR
2024-02-144ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
Code (U): 17,063,000 · Code (U): 650,600EDGAR
2023-11-074Shakespeare William — See RemarksOption exercise (M): 251,084 @ $0.32 · Option exercise (M): 251,084 (derivative) @ $0EDGAR
2023-07-194Foresite Capital Management V, LLC — 10% owner
Foresite Capital Fund V, L.P. — 10% owner
Foresite Capital Opportunity Fund V, L.P. — 10% owner
Foresite Capital Opportunity Management V, LLC — 10% owner
Tananbaum James B. — 10% owner
Purchase (P): 523,450 @ $2.97 · Purchase (P): 176,550 @ $2.97EDGAR
2023-07-194GORDON CARL L — Director, 10% ownerPurchase (P): 328,482 @ $3.05 · Purchase (P): 151,450 @ $3.05EDGAR
2023-07-194ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
Purchase (P): 328,482 @ $3.05 · Purchase (P): 151,450 @ $3.05EDGAR
2023-06-134Yi Kathy — DirectorGrant/award (A): 19,500 (derivative) @ $0 · Grant/award (A): 3,250 (derivative) @ $0EDGAR
2023-06-134Dukes Iain D. — DirectorGrant/award (A): 19,500 (derivative) @ $0 · Grant/award (A): 3,250 (derivative) @ $0EDGAR
2023-06-134Stein Steven H — DirectorGrant/award (A): 19,500 (derivative) @ $0 · Grant/award (A): 3,250 (derivative) @ $0EDGAR
2023-06-134GORDON CARL L — Director, 10% ownerGrant/award (A): 19,500 (derivative) @ $0 · Grant/award (A): 3,250 (derivative) @ $0EDGAR
2023-06-134HAYDEN DONALD J JR — DirectorGrant/award (A): 19,500 (derivative) @ $0 · Grant/award (A): 3,250 (derivative) @ $0EDGAR
2023-03-024Rivera Victor — Chief Scientific OfficerGrant/award (A): 16,250 (derivative) @ $0EDGAR
2023-03-024Shakespeare William — See RemarksGrant/award (A): 21,250 (derivative) @ $0EDGAR
2023-03-024Kerstein David — Chief Medical OfficerGrant/award (A): 17,500 (derivative) @ $0EDGAR
2023-03-024Dahms Bradford D. — Chief Financial OfficerGrant/award (A): 17,500 (derivative) @ $0EDGAR
2023-03-024CLACKSON TIMOTHY P — President and CEO, DirectorGrant/award (A): 45,625 (derivative) @ $0EDGAR
2023-02-214Shakespeare William — See RemarksGrant/award (A): 127,500 (derivative) @ $0EDGAR
2023-02-214Rivera Victor — Chief Scientific OfficerGrant/award (A): 97,500 (derivative) @ $0EDGAR
2023-02-214Kerstein David — Chief Medical OfficerGrant/award (A): 105,000 (derivative) @ $0EDGAR
2023-02-214Dahms Bradford D. — Chief Financial OfficerGrant/award (A): 105,000 (derivative) @ $0EDGAR
2023-02-214CLACKSON TIMOTHY P — President and CEO, DirectorGrant/award (A): 273,750 (derivative) @ $0EDGAR
2023-01-034Foresite Capital Management V, LLC — 10% owner
Foresite Capital Fund V, L.P. — 10% owner
Foresite Capital Opportunity Fund V, L.P. — 10% owner
Foresite Capital Opportunity Management V, LLC — 10% owner
Tananbaum James B. — 10% owner
Purchase (P): 250,000 @ $5 · Purchase (P): 250,000 @ $5EDGAR
2023-01-034HAYDEN DONALD J JR — DirectorPurchase (P): 100 @ $5 · Purchase (P): 9,900 @ $5.00EDGAR
2022-12-014Dahms Bradford D. — Chief Financial OfficerPurchase (P): 1,502.19 @ $6.66EDGAR
2022-11-144CLACKSON TIMOTHY P — President and CEO, DirectorPurchase (P): 2,500 @ $6.80EDGAR
2022-11-094GORDON CARL L — Director, 10% ownerPurchase (P): 192,000 @ $5.21EDGAR
2022-11-094ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
Purchase (P): 192,000 @ $5.21EDGAR
2022-10-194Stein Steven H — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2022-06-134Yi Kathy — DirectorGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-06-134Dukes Iain D. — Chairman, DirectorGrant/award (A): 30,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0EDGAR
2022-06-134GORDON CARL L — Director, 10% ownerGrant/award (A): 30,000 (derivative) @ $0EDGAR
2022-05-184HAYDEN DONALD J JR — DirectorGrant/award (A): 60,000 (derivative) @ $0EDGAR
2022-02-234Kerstein David — Chief Medical OfficerGrant/award (A): 150,000 (derivative) @ $0EDGAR
2022-02-234Dalgarno David — Chief Technical OfficerGrant/award (A): 130,000 (derivative) @ $0EDGAR
2022-02-234Dahms Bradford D. — Chief Financial OfficerGrant/award (A): 150,000 (derivative) @ $0EDGAR
2022-02-234Shakespeare William — See RemarksGrant/award (A): 180,000 (derivative) @ $0EDGAR
2022-02-234Rivera Victor — Chief Scientific OfficerGrant/award (A): 130,000 (derivative) @ $0EDGAR
2022-02-234CLACKSON TIMOTHY P — President and CEO, DirectorGrant/award (A): 450,000 (derivative) @ $0EDGAR
2022-01-214GORDON CARL L — Director, 10% ownerPurchase (P): 11,521 @ $9.97 · Purchase (P): 35,000 @ $9.95 · Purchase (P): 111,896 @ $9.97EDGAR
2022-01-214ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
Purchase (P): 11,521 @ $9.97 · Purchase (P): 35,000 @ $9.95 · Purchase (P): 111,896 @ $9.97EDGAR
2022-01-134GORDON CARL L — Director, 10% ownerPurchase (P): 1,600 @ $9.81 · Purchase (P): 6,900 @ $10.67 · Purchase (P): 18,897 @ $10.06 · Purchase (P): 17,320 @ $9.43EDGAR
2022-01-134ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
Purchase (P): 1,600 @ $9.81 · Purchase (P): 6,900 @ $10.67 · Purchase (P): 18,897 @ $10.06 · Purchase (P): 17,320 @ $9.43EDGAR
2021-12-224Dahms Bradford D. — Chief Financial OfficerPurchase (P): 1,970.04 @ $10.15EDGAR
2021-12-224CLACKSON TIMOTHY P — President and CEO, DirectorPurchase (P): 2,600 @ $9.76EDGAR
2021-10-154TAKEDA PHARMACEUTICAL CO LTD — 10% owner
ARIAD PHARMACEUTICALS INC — 10% owner
Conversion (C): 1,615,427 · Conversion (C): 1,615,427 (derivative) @ $0EDGAR

Recent 8-K events — Theseus Pharmaceuticals, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-02-148-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-12-228-K1.01 — Entry into a Material Definitive Agreement
1.02 — Termination of a Material Definitive Agreement
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2023-12-048-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2023-11-278-K8.01 — Other EventsEDGAR
2023-11-138-K2.02 — Results of Operations and Financial Condition
?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-10-318-K1.02 — Termination of a Material Definitive AgreementEDGAR
2023-08-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2023-07-138-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-06-098-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2023-05-258-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=THRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs